佟敬山

个人简历

佟敬山，教授，博士生导师。2004年本科毕业于大连医科大学，2008年硕士毕业于长春理工大学，2011年博士毕业于吉林大学。2012-2017年于美国匹兹堡大学从事博士后研究，2017-2018年为匹兹堡大学Research Scientist，2018年-2022年为匹兹堡大学讲师。2022年7月加入老葡萄京官网。目前课题组研究方向为肿瘤生物治疗，肿瘤免疫治疗及肿瘤预防等。近年来在Cancer Research，Oncogene，Nature Communications，PNAS，Cell Death & Differentiation等著名期刊发表学术论文25篇。其中包括第一作者论文7篇。论文他引次数近1200次。

承担科研课题

徐州医科大学海外高层次人才（D类）科研启动基金，100万元，主持

近五年代表性论文、专著

1.      Tong J, Tan X, Hao S, Ermine K, Lu X, Liu Z, Jha A, Yu J, Zhang L^*. Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction. Oncogene. 2023 Jan 31. doi: 10.1038/s41388-023-02598-6.

2.      Tong J, Tan X, Song X, Gao M, Risnik D, Hao S, Ermine K, Wang P, Li H, Huang Y, Yu J, Zhang L*. CDK4/6 inhibition induces p73/DR5-mediated immunogenic cell death to potentiate chemotherapy and immune checkpoint blockade. Cancer Research. 2022 Apr 1;82(7):1340-1352.

3.      Tong J, Tan X, Risnik D, Gao M, Song X, Ermine K, Shen L, Wang S, Yu J, Zhang L*. BET degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. Oncogene. 2021 Dec;40(48):6566-6578.

4.      Tong J, Zheng X, Tan X, Fletcher R, Nikolovska-Coleska Z, Yu J, Zhang L*. Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-only proteins. Cancer Research. 2018; 78(16):4704-4715.

5.      Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F, Yu J, Zhang L*. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Research. 2017;77(9):2512-2521.

6.      Tong J^#, Tan S^#, Nikolovska-Coleska Z, Yu J, Zou F^*, Zhang L^*. FBW7-ependent Mcl-1 degradation mediates the anticancer effect of Hsp90 inhibitors. Molecular Cancer Therapeutics. 2017; 16(9):1979-1988.

7.      Tong J, Tan S, Zou F, Yu J, Zhang L^*. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene. 2017; 36(6):787-796.